Target intelligence / Profile preview

phosphatidylinositol glycan anchor biosynthesis class C pseudogene 2 (PIGCP2)

Target: PIGCP2

Overview

phosphatidylinositol glycan anchor biosynthesis class C pseudogene 2 (PIGCP2) appears to represent a non-coding pseudogene in the human genome, named similarly to members of the PIG (phosphatidylinositol glycan anchor biosynthesis) gene family. These typically function in GPI-anchor biosynthesis, but pseudogenes like PIGCP2 do not encode functional proteins and are not considered drug targets or involved in disease biology. There is no evidence in established genomic, proteomic, or pharmaceutical databases for PIGCP2 fulfilling the criteria of a therapeutic target or active biological function[6][5].

Beyond the preview

Go deeper on phosphatidylinositol glycan anchor biosynthesis class C pseudogene 2 (PIGCP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phosphatidylinositol glycan anchor biosynthesis class C pseudogene 2 (PIGCP2).

Explore the full profile